Hillhouse Capital Management Ltd. Boosts Stake in Clearside Biomedical, Inc. (CLSD)
Hillhouse Capital Management Ltd. raised its stake in Clearside Biomedical, Inc. (NASDAQ:CLSD) by 5.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 900,000 shares of the company’s stock after acquiring an additional 45,100 shares during the quarter. Hillhouse Capital Management Ltd. owned approximately 3.56% of Clearside Biomedical worth $8,199,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the company. ProShare Advisors LLC raised its position in Clearside Biomedical by 4.0% in the second quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock valued at $135,000 after purchasing an additional 563 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Clearside Biomedical by 10.8% during the first quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock valued at $277,000 after purchasing an additional 3,404 shares in the last quarter. Marshall Wace North America L.P. boosted its stake in shares of Clearside Biomedical by 1.9% during the second quarter. Marshall Wace North America L.P. now owns 218,960 shares of the company’s stock valued at $1,971,000 after purchasing an additional 4,010 shares in the last quarter. TIAA CREF Investment Management LLC grew its holdings in shares of Clearside Biomedical by 30.7% during the first quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after purchasing an additional 4,527 shares during the last quarter. Finally, Nationwide Fund Advisors grew its holdings in shares of Clearside Biomedical by 118.3% during the second quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after purchasing an additional 6,343 shares during the last quarter. 52.45% of the stock is owned by hedge funds and other institutional investors.
Clearside Biomedical, Inc. (NASDAQ CLSD) traded down 2.38% during trading on Wednesday, hitting $8.60. The company had a trading volume of 69,444 shares. Clearside Biomedical, Inc. has a 1-year low of $6.50 and a 1-year high of $25.08. The stock’s market capitalization is $217.89 million. The company’s 50 day moving average price is $8.10 and its 200-day moving average price is $8.10.
Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.13). Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. The business had revenue of $0.13 million during the quarter. On average, analysts expect that Clearside Biomedical, Inc. will post ($2.10) EPS for the current year.
In other news, CEO Daniel H. White sold 3,600 shares of Clearside Biomedical stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $9.79, for a total value of $35,244.00. Following the transaction, the chief executive officer now owns 499,967 shares in the company, valued at $4,894,676.93. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Gerald D. Cagle acquired 5,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The stock was bought at an average price of $7.08 per share, for a total transaction of $35,400.00. Following the acquisition, the director now owns 15,941 shares of the company’s stock, valued at approximately $112,862.28. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 7,100 shares of company stock worth $50,170 and sold 100,600 shares worth $788,844. 20.90% of the stock is owned by company insiders.
Several research analysts have recently issued reports on the company. TheStreet downgraded Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Clearside Biomedical in a research report on Monday, August 7th. Zacks Investment Research lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, ValuEngine raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $19.00.
Clearside Biomedical Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.